唑来膦酸单药治疗肺癌合并骨转移的临床研究  

Clinical Research on the Zoledronic Acid Monotherapy in the Treatment of Lung Cancer Combined with Bone Metastasis

作　　者：何文[1] 魏伟宏[1] 张红雨[1] 

机构地区：[1]广东省佛山市第一人民医院,广东佛山528000

出　　处：《肿瘤药学》2013年第5期375-377,共3页Anti-Tumor Pharmacy

摘　　要：目的探讨唑来膦酸单药治疗肺癌合并骨转移的临床疗效。方法将56例肺癌合并骨转移的患者随机分为两组,分别使用唑来膦酸和帕米膦酸单药静脉滴注治疗,治疗3个月后,比较两组患者的疼痛治疗效果、生活质量评分(QOL)、一般状况评分(KPS)及不良反应的发生情况。结果两组的疼痛治疗有效率、不良反应的发生率比较,差异均无统计学意义(P>0.05)。两组患者治疗后的QOL和KPS评分与治疗前比较,差异有统计学意义(P<0.05),但两组之间QOL和KPS评分比较,差异无统计学意义(P<0.05)。结论唑来膦酸可有效缓解肺癌并骨转移患者的疼痛,综合疗效与帕米膦酸相当。Objective To investigate the clinical effects of zoledronic acid monotherapy on the lung cancer combined with bone metastasis. Methods Fifty-sLx cases of lung cancer patients with bone metastasis were randomly divided into two groups. The experimental group was treated by zoledronic acid and the control group by pamidronate infusion therapy. The efficiency of pain treatment, quality of life（QOL）, Karnof^ky performance score （KPS） and the incidence of adverse reactions were compared between the two groups. Results No significant differences were found in the efficiency of pain treatment and incidence rate of adverse reactions between the two groups （P〉0.05）. After treatment, the QOL and KPS of two groups were significantly dif- ferent from those before treatment （P〈0.05）, but had no significant differences between the two groups （P〉0.05）. Conclusion Zoledronic acid monotherapy could effectively alleviate pains of lung cancer patients with bone metastasis. It had equal analgesia effect as pamidronate in the treatment.

关 键 词：唑来膦酸 单药治疗 肺癌 骨转移 

分 类 号：R734.2[医药卫生—肿瘤]